WebSite Ethiopia

Monday, October 24, 2016

Luveris

Luveris is a brand name of lutropin alfa, approved by the FDA in the following formulation(s):

LUVERIS (lutropin alfa - injectable; subcutaneous)

Manufacturer: EMD SERONO

Approval date: October 8, 2004

Strength(s): 75 IU/VIAL ^[RLD]

Has a generic version of Luveris been approved?

No. There is currently no therapeutically equivalent version of Luveris available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Luveris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
Patent 5,767,251
Issued: June 16, 1998
Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
Assignee(s): Genzyme Corporation
Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
Patent expiration dates:
- June 16, 2015
  ✓
  Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 8, 2011 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Lovaza been approved?

No. There is currently no therapeutically equivalent version of Lovaza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovaza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Fatty acid composition
Patent 5,502,077
Issued: March 26, 1996
Inventor(s): Breivik; Harald & Borretzen; Bernt & Dahl; Knut H. & Krokan; Hans E. & Bonaa; Kaare H.
Assignee(s): Norsk Hydro A.S.
Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
Patent expiration dates:
- March 26, 2013
  ✓
  Patent use: USE IN LIPID MANAGEMENT
  ✓
  Drug substance

Fatty acid composition
Patent 5,656,667
Issued: August 12, 1997
Inventor(s): Breivik; Harald & B.o slashed.rretzen; Bernt & Dahl; Knut Helk.ang.s & Krokan; Hans Einar & B.o slashed.naa; Kaare Harald
Assignee(s): Norsk Hydro as
Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
Patent expiration dates:
- April 10, 2017
  ✓
  Patent use: USE IN LIPID MANAGEMENT
  ✓
  Drug substance
  ✓
  Drug product

Pharmaceutical composition comprising low concentrations of environmental pollutants
Patent 7,732,488
Issued: June 8, 2010
Inventor(s): Breivik; Harald & Thorstad; Olav
Assignee(s): Pronova Biopharma Norge AS
The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
Patent expiration dates:
- January 30, 2025
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- September 16, 2012 - INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION

Has a generic version of LoSeasonique been approved?

A generic version of LoSeasonique has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to LoSeasonique and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Manufacturer: LUPIN LTD

Approval date: October 26, 2011

Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Manufacturer: WATSON LABS

Approval date: October 25, 2011

Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of LoSeasonique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Patent 7,615,545
Issued: November 10, 2009
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
Assignee(s): Duramed Pharmaceuticals, Inc.
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Patent expiration dates:
- June 15, 2023
  ✓
  Patent use: PREVENTION OF PREGNANCY

Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Patent 7,855,190
Issued: December 21, 2010
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole S. & Iskold; Beata & Bronnenkant; Lance J. & Hait; Howard & Reape; Kathleen Z.
Assignee(s): Teva Women's Health, Inc.
The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Patent expiration dates:
- December 5, 2028
  ✓
  Patent use: PREVENTION OF PREGNANCY

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Patent 7,858,605
Issued: December 28, 2010
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
Assignee(s): Teva Women's Health, Inc.
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Patent expiration dates:
- June 23, 2023
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- October 24, 2011 - NEW PRODUCT

Has a generic version of Lybrel been approved?

A generic version of Lybrel has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lybrel and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Manufacturer: WATSON LABS

Approval date: June 6, 2011

Strength(s): 0.02MG;0.09MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lybrel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Hormonal contraceptive
Patent 6,500,814
Issued: December 31, 2002
Inventor(s): Rolf-Dieter; Hesch
Assignee(s): Wyeth Pharmaceuticals
The present invention relates to a hormonal contraceptive product having two hormonal components, an estrogen and a gestagen, and a process for the combined, continuous administration of the product of the invention.
Patent expiration dates:
- September 3, 2018
  ✓
  Patent use: PREVENTION OF PREGNANCY

Has a generic version of Restoril been approved?

Yes. The following products are equivalent to Restoril:

temazepam capsule; oral

Manufacturer: ACTAVIS ELIZABETH

Approval date: August 7, 1987

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: September 8, 2009

Strength(s): 7.5MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: September 14, 2009

Strength(s): 22.5MG ^[AB]

Manufacturer: MYLAN

Approval date: July 7, 1986

Strength(s): 15MG ^[AB]

Manufacturer: MYLAN

Approval date: July 10, 1986

Strength(s): 30MG ^[AB]

Manufacturer: MYLAN

Approval date: June 12, 2009

Strength(s): 22.5MG ^[AB]

Manufacturer: MYLAN

Approval date: May 21, 2010

Strength(s): 7.5MG ^[AB]

Manufacturer: NOVEL LABS INC

Approval date: April 21, 1987

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: SANDOZ

Approval date: January 12, 1988

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: WATSON LABS

Approval date: May 21, 1993

Strength(s): 15MG ^[AB], 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Restoril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Restoril.

Has a generic version of Azor been approved?

No. There is currently no therapeutically equivalent version of Azor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
Patent 5,616,599
Issued: April 1, 1997
Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
Assignee(s): Sankyo Company, Limited
Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
Patent expiration dates:
- April 25, 2016
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug substance
  ✓
  Drug product
- October 25, 2016
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- September 26, 2010 - NEW COMBINATION

Has a generic version of Differin been approved?

A generic version of Differin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Differin and have been approved by the FDA:

adapalene cream; topical

Manufacturer: FOUGERA PHARMS

Approval date: June 30, 2010

Strength(s): 0.1% ^[AB]

adapalene gel; topical

Manufacturer: GLENMARK GENERICS

Approval date: July 1, 2010

Strength(s): 0.1% ^[AB]

Manufacturer: PLIVA HRVATSKA DOO

Approval date: June 2, 2010

Strength(s): 0.1% ^[AB]

Note: No generic formulation of the following product is available.

adapalene - lotion; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Differin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,579,377
Issued: August 25, 2009
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- February 23, 2025
  ✓
  Patent use: TOPICAL TREATMENT OF ACNE VULGARIS

Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,737,181
Issued: June 15, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- August 29, 2024
  ✓
  Drug product

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Patent 7,834,060
Issued: November 16, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,838,558
Issued: November 23, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development S.N.C.
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Drug product

Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
Patent 7,868,044
Issued: January 11, 2011
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Patent 7,998,467
Issued: August 16, 2011
Inventor(s): Mallard; Claire & Ferrara; Eve
Assignee(s): Galderma Research & Development
Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Patent expiration dates:
- May 31, 2028
  ✓
  Patent use: TREATMENT OF ACNE
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- March 17, 2013 - NEW DOSAGE FORM

Monday, October 24, 2016

Luveris

LUVERIS (lutropin alfa - injectable; subcutaneous)

Has a generic version of Luveris been approved?

Related Patents

Related Exclusivities

See also...

Lovaza

LOVAZA (omega-3-acid ethyl esters - capsule; oral)

Has a generic version of Lovaza been approved?

Related Patents

Related Exclusivities

See also...

LoSeasonique

LOSEASONIQUE (ethinyl estradiol; levonorgestrel - tablet; oral)

Has a generic version of LoSeasonique been approved?

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Related Patents

Related Exclusivities

See also...

Lybrel

LYBREL (ethinyl estradiol; levonorgestrel - tablet; oral)

Has a generic version of Lybrel been approved?

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Related Patents

See also...

Restoril

RESTORIL (temazepam - capsule; oral)

Has a generic version of Restoril been approved?

temazepam capsule; oral

Related Patents

See also...

Azor

AZOR (amlodipine besylate; olmesartan medoxomil - tablet; oral)

Has a generic version of Azor been approved?

Related Patents

Related Exclusivities

See also...

Differin

DIFFERIN (adapalene - cream; topical)

DIFFERIN (adapalene - gel; topical)

DIFFERIN (adapalene - lotion; topical)

Has a generic version of Differin been approved?

adapalene cream; topical

adapalene gel; topical

Related Patents

Related Exclusivities

See also...